ProductNum | picture | CAS No. | Name and description | Size | Formula | Quick order |
---|---|---|---|---|---|---|
GC31638-20mg |
|
539813-69-9 |
PPAR agonist 1
|
0 | C20H25NO6S | |
GC31638-10mg |
|
539813-69-9 |
PPAR agonist 1
|
0 | C20H25NO6S | |
GC31638-5mg |
|
539813-69-9 |
PPAR agonist 1
|
0 | C20H25NO6S | |
GC31638-1mg |
|
539813-69-9 |
PPAR agonist 1
|
0 | C20H25NO6S | |
GC31637-5mg |
|
24880-45-3 |
Docosapentaenoic acid 22n-3
|
0 | C22H34O2 | |
GC31637-1mg |
|
24880-45-3 |
Docosapentaenoic acid 22n-3
|
0 | C22H34O2 | |
GC31636-100mg |
|
604-33-1 |
Cholesteryl linoleate
|
0 | C45H76O2 | |
GC31634-10mg |
|
1147729-48-3 |
GPR40 Agonist 2
|
0 | C24H30O3 | |
GC31634-5mg |
|
1147729-48-3 |
GPR40 Agonist 2
|
0 | C24H30O3 | |
GC31634-1mg |
|
1147729-48-3 |
GPR40 Agonist 2
|
0 | C24H30O3 | |
GC31633-1mg |
|
170365-25-0 |
KW-8232 free base
|
0 | C36H37ClN4O3 | |
GC31632-100mg |
|
88-14-2 |
2-Furoic acid (Furan-2-carboxylic acid)
|
0 | C5H4O3 | |
GC31631-5mg |
|
10094-58-3 |
Stachyose tetrahydrate
|
0 | C24H50O25 | |
GC31631-10mM(1mLinDMSO) |
|
10094-58-3 |
Stachyose tetrahydrate
|
0 | C24H50O25 | |
GC31630-100mg |
|
20312-36-1 |
(S)-2-Hydroxy-3-phenylpropanoic acid
|
0 | C9H10O3 | |
GC31630-10mM(1mLinDMSO) |
|
20312-36-1 |
(S)-2-Hydroxy-3-phenylpropanoic acid
|
0 | C9H10O3 | |
GC31629-10mg |
|
455957-28-5 |
MC-4R Agonist 1
|
0 | C30H38ClF2N3O2 | |
GC31629-5mg |
|
455957-28-5 |
MC-4R Agonist 1
|
0 | C30H38ClF2N3O2 | |
GC31629-1mg |
|
455957-28-5 |
MC-4R Agonist 1
|
0 | C30H38ClF2N3O2 | |
GC31628-20mg |
|
391610-37-0 |
MCHr1 antagonist 1
|
0 | C28H33F2N5O5 | |